Progress in research of long-term protective efficacy of human papillomavirus vaccine.
10.3760/cma.j.cn112338-20221025-00905
- Author:
Xin Hua JIA
1
;
Xue Feng KUANG
1
;
Ya Han CHEN
2
;
Yu Fei LI
1
;
Zhao Feng BI
3
;
Ting WU
3
;
You Lin QIAO
4
Author Information
1. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
2. Yanjing Medical College, Capital Medical University, Beijing 101300, China.
3. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China.
4. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China Center for Global Health, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Human Papillomavirus Viruses;
Biomedical Research;
Papillomavirus Vaccines
- From:
Chinese Journal of Epidemiology
2023;44(5):851-854
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of HPV vaccine in preventing cervical cancer has been demonstrated in numerous clinical trials and clinical uses. The follow-up after clinical trials usually last for 5-6 years to evaluate the long-term efficacy, and a series of long-term follow-up studies have been conducted in some regions. The literature retrieval of HPV vaccine long term efficiency research both at home and abroad indicated that the protective efficacy of the vaccine against vaccine-type-related cervical intraepithelial neoplasia grade 2 and above is higher than 90%.
